Whether acalatinib is a targeted drug and an introduction to its mechanism of action

Acalabrutinib (also known as Acalabrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor. It is a typical targeted therapy drug and is mainly used to treat certain types of B cell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is the second generation BTK inhibitor developed after ibrutinib. It retains anti-cancer activity while optimizing selectivity and side effects profile.

The mechanism of action of acotinib is mainly by irreversibly inhibiting BTK protein activity and blocking the B cell receptor (BCR) signaling pathway. BTK plays a key role in the growth, differentiation and survival of B cells. When this pathway is continuously activated, it will lead to abnormal proliferation of B cells, thus forming malignant tumors. Acotinib binds to BTK with high selectivity, inhibits its activity, causes tumor cells to undergo apoptosis or stop proliferation, and effectively controls the disease.

Compared with the first-generation BTK inhibitor ibrutinib, acotinib is more selective for BTK and is more selective for other tyrosine kinases such asEGFR or ITK is less inhibited, which means that the clinical side effects it causes, such as bleeding, arrhythmia, rash, etc., are relatively mild and are better tolerated by patients. Therefore, acotinib is considered a safer and more targeted new generation treatment option, especially for patients who cannot tolerate ibrutinib.

In short, acotinib is a clear targeted drug that interferes with the growth and survival of tumor cells by precisely targeting the BTK pathway. With the accumulation of more research data and expansion of indications, it has gradually become an important part of the treatment plan for B-cell malignancies. Patients should undergo genetic testing and physician evaluation before using acotinib to ensure clear treatment targets and optimal efficacy.

Reference materials:https://www.drugs.com